1. Home
  2. DAVA vs SENS Comparison

DAVA vs SENS Comparison

Compare DAVA & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$4.16

Market Cap

220.4M

Sector

Technology

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$5.03

Market Cap

213.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAVA
SENS
Founded
2000
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
EDP Services
Industrial Machinery/Components
Sector
Technology
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
220.4M
213.2M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
DAVA
SENS
Price
$4.16
$5.03
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$13.50
$18.38
AVG Volume (30 Days)
216.5K
565.7K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,389,000.00
Revenue This Year
N/A
$74.15
Revenue Next Year
$4.07
$58.60
P/E Ratio
$20.02
N/A
Revenue Growth
N/A
19.85
52 Week Low
$3.98
$0.41
52 Week High
$20.80
$8.75

Technical Indicators

Market Signals
Indicator
DAVA
SENS
Relative Strength Index (RSI) 40.04 27.46
Support Level N/A $0.43
Resistance Level $7.04 $8.68
Average True Range (ATR) 0.22 0.33
MACD -0.03 -0.19
Stochastic Oscillator 17.43 2.61

Price Performance

Historical Comparison
DAVA
SENS

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: